title: Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.
abstract: BACKGROUND
  Preventing and managing chemotherapy-induced nausea and vomiting (CINV) remain important goals. The objective of the Pan Australasian chemotherapy-induced emesis burden of illness (PrACTICE) study was to describe the incidence of CINV after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in current clinical practice in Australia and five Asian countries (China, India, Singapore, South Korea, and Taiwan).
  
  
  METHODS
  This prospective, observational study of CINV was conducted at 31 sites in these six countries from August 2011 through September 2012 and enrolled male and female adult patients (≥18 years of age) naïve to HEC and MEC who were scheduled to receive at least two cycles of single-day chemotherapy. The primary effectiveness endpoint was complete response, defined as no vomiting or use of rescue therapy, during chemotherapy cycle 1 in the overall phase (0-120 h), acute phase (0-24 h), and delayed phase (>24-120 h). Study outcomes were analyzed descriptively. Primary outcomes, CINV incidence, and treatment patterns (chemotherapy, CINV prophylaxis, rescue medication prescription, and rescue medication use) were assessed by phase (overall, acute, delayed), by cycle (as appropriate), within and across countries, and by level of chemotherapy emetogenicity (HEC vs. MEC). The impact of CINV in cycle 1 on CINV in cycle 2 was analyzed for all patients with evaluable data for cycle 2. No site-specific analyses were performed. The remainder of this special series of papers reports on the results of this study.
authors.affiliation: Faculty of Health Sciences, University of Adelaide, North Terrace, Adelaide, SA, 5000, Australia, dorothy.keefe@health.sa.gov.au.
authors.forename: Dorothy M K
authors.initials: DM
authors.lastname: Keefe
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
authors.forename: Hoon-Kyo
authors.initials: HK
authors.lastname: Kim
authors.forename: Ruey Kuen
authors.initials: RK
authors.lastname: Hsieh
authors.forename: Shiying
authors.initials: S
authors.lastname: Yu
authors.forename: Yachuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Nicholls
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Burke
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D002681:China / Q000453:epidemiology; D017281:Cost of Illness; D005260:Female; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D056910:Republic of Korea / Q000453:epidemiology; D011795:Surveys and Questionnaires; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents